AXIS Capital Limited (AXS)

Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AX...

AXIS Capital gains from a well-performing specialty insurance, reinsurance as well as the accident and health portfolio.

Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock?

London, United Kingdom--(Newsfile Corp. - February 25, 2025) - Edison issues report on Accsys Technologies (AIM: AXS). At its investor strategy day, Accsys set financial targets for the coming years, ...

AXIS Capital stock is poised to gain from a well-performing specialty insurance, reinsurance as well as the accident and health portfolio.

Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity ...

AXIS Capital Holdings Limited (NYSE:AXS ) Q4 2024 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Cliff Gallant - Head, Investor Relations Vince Tizzio - President and Chief ...

AXS' fourth-quarter results reflect improved net investment income and higher premiums, offset by higher expenses.

While the top- and bottom-line numbers for Axis Capital (AXS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics co...

Axis Capital (AXS) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.68 per share. This compares to earnings of $2.94 per share a year ago.